An intravenous humanized anti-CD20 monoclonal antibody for the treatment of rheumatoid arthritis.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Prevnar 13 (13-Valent Pneumococcal Conjugate Vaccine)
A next-generation vaccine for broader protection against pneumococcal diseases in young children.
Aquilion® ONE Dynamic Volume Computed Tomography System
A computed tomography system that uses 320 detectors to acquire image data as one continuous volume, rather than in slices, intended for general-purpose, advanced, and whole-organ imaging.
Liraglutide (Victoza®)
A subcutaneously administered drug for the treatment of type 2 diabetes mellitus.
Brilliance iCT 256-Slice Computed Tomography (CT) System
A 256-slice computed tomography system intended for general-purpose and advanced imaging applications, including whole-organ imaging, in approximately 1 or 2 seconds.
Actemra® (Tocilizumab) for Rheumatoid Arthritis
An intravenous monoclonal antibody to the interleukin-6 receptor for the second- or third-line treatment of adult patients with moderate-to-severe rheumatoid arthritis.
Ceftobiprole (BAL5788)
An intravenous antibiotic for the treatment of complicated skin and skin structure infections due to gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.
Idrabiotaparinux (Biotinylated Idraparinux)
A fixed-dose, once-weekly, subcutaneously administered anticoagulant for the treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep vein thrombosis or pulmonary embolism.
Oncotype DX® Colon Cancer Assay
A gene expression assay performed on excised tumor tissue to improve risk stratification of patients with resected stage II colon cancer.
Cimzia® (Certolizumab Pegol) for Rheumatoid Arthritis (RA)
A subcutaneously administered anti–tumor necrosis factor monoclonal antibody for the second- or third-line treatment of adult patients with moderate-to-severe rheumatoid arthritis.